An FDA panel is scheduled to meet in September to discuss potential side-effects of a number of osteoporosis drugs—including Fosamax—which may contribute to the risk of bone fractures and other problems with long-term use. There is growing evidence of a link between the class of drugs known as bisphosphonates—which are designed in part to strengthen bones—and an increased risk of subtrochanteric and diaphyseal femur fractures. These types of fractures are rare and potentially more dangerous than other types of femur fractures. Subtrochanteric fractures are fractures that occur on the femur just below the hip joint. Specialized implants are often required to treat subtrochanteric fractures, and many people who suffer subtrochanteric fractures never heal to their previous condition. Diasphyseal fractures occur on the midsection of the femur and, though more common, can likewise involve a long and difficult healing process. While it remains unclear how—or even if—bisphosphonates are contributing to greater instances of femur fractures among patients prescribed the drugs, there has been enough evidence of the risk t o prompt the FDA to issue new warning label requirements and schedule an in-depth review. A number of patients nationwide have already filed lawsuits against Merck, the makers of Fosamax, and other drug companies who produce bisphosphonate osteoporosis medication. If you have taken Fosamax and sustained a femur fracture, please contact the experienced Mobile, Alabama, defective drug attorneys at Long & Long, to schedule your free case evaluation.